Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Amgen | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Amgen

Revenues up 5% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Amgen

2Q Revenues: $4.7 billion (+5%)

2Q Earnings: $1.3 billion (-1%)

YTD Revenues: $8.7 billion (+8%)

YTD Earnings: $2.7 billion (+10%)

Comments: Combined Neulasta and Neupogen sales increased 7% to $1.4 billion in the quarter. Enbrel sales increased 9% to $1.2 billion. Sensipar/Mimpara sales increased 12% to $259 million. XGEVA sales increased 39% to $249 million and Prolia sales increased 57% to $188 million. Aranesp sales decreased 2% to $524 million and Epogen sales were down 4% to $502 million as a result of a Medicaid rebate adjustment. Other revenues were lower by $193 million as a result of a payment from Takeda recognized in 2Q12. R&D expenses were up 17% in the quarter, primarily to support later-stage clinical programs, including AMG 145.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters